tldrdailynews.com logo

Coherus Biosciences Sells Ophthalmology Franchise to Sandoz for $170M

1 min read
Source: GlobeNewswire
Coherus Biosciences Sells Ophthalmology Franchise to Sandoz for $170M
Photo: GlobeNewswire
TL;DR

Coherus BioSciences, Inc. has agreed to sell its ophthalmology franchise, including CIMERLI, to Sandoz for $170 million in cash, aligning with its strategic focus on oncology. The divestiture aims to pay down debt, reduce interest costs, and allow the company to concentrate on its core therapeutic area. Coherus' oncology assets include UDENYCA and LOQTORZI, and the transaction is expected to close in the first half of 2024, subject to certain conditions and approvals.

Topics:business#business#coherus#divestiture#oncology#ophthalmology#sandoz
Share this article
  1. Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal  GlobeNewswire
  2. M & A News: Coherus (NASDAQ:CHRS) Surges after $170M Deal with Sandoz - TipRanks.com  TipRanks
  3. Sandoz buys Coherus' Lucentis biosimilar Cimerli for $170M  FiercePharma
  4. Why Coherus Biosciences Popped Today  The Motley Fool
  5. Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market  Financial Post

Want the full story? Read the original reporting

Read on GlobeNewswire